Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies
18. April 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, April 18, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today new, promising results from a preclinical trial conducted in...
Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
12. April 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, April 12, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive results from the Company’s phase II clinical trial of...
Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
16. März 2017 08:00 ET
|
Protalix BioTherapeutics, Inc.
Current Cash is projected to Fund the Company through Three Clinical Trial Read-Outs and into 2019 CARMIEL, Israel, March 16, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX)...
Protalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16, 2017
09. März 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 09, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of...
Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders
14. Februar 2017 16:12 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that its board of directors approved the record date for the Company’s...
Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017
13. Februar 2017 07:00 ET
|
Protalix BioTherapeutics, Inc.
Data to be presented in three oral presentations and two poster presentations CARMIEL, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced...
Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017
09. Januar 2017 06:00 ET
|
Protalix BioTherapeutics, Inc.
Full Switch Plan Initiated and Published by Brazilian Ministry of Health for Gaucher Patients in Brazil Yielding Significant Revenue Stream Fabry Phase III Clinical Trial Underway with Interim...
Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
03. Januar 2017 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company’s phase II clinical trial of...
Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil
27. Dezember 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today the confirmation of the recent letter of intent to...
Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis
22. Dezember 2016 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the last patient has been enrolled in the Company’s phase II...